Type 1 Diabetes TrialNet
Trialnet is a network of researchers who are dedicated to learning how type 1 diabetes can be prevented in relatives of people with type 1 diabetes. Relatives have a higher chance of developing the disease when compared to the general population. TrialNet is currently offering 3 prevention studies to those who are at risk of developing the disease.
TrialNet is working to find ways to delay or prevent type 1 diabetes in people at risk.
Type 1 diabetes is an autoimmune disease that happens when the immune system attacks and destroys the body’s insulin-producing cells. Proteins in the blood, called autoantibodies, are signs of this destruction. TrialNet offers a screening test that can detect these autoantibodies up to 10 years before diagnosis.
You can find out if you and your family are at risk for type 1 diabetes.
Screening is the first step on the pathway to prevention. You can be screened by TrialNet if you are:
1 to 45 years old AND have a parent, child, brother, or sister with type 1 diabetes
1 to 20 years old AND have a niece, nephew, aunt, uncle, grandparent, half-brother, half-sister, or cousin with type 1 diabetes
How to Get Screened:
- TrialNet has more than 200 study locations around the world. To find the one closest to you call (toll-free) 1.866.699.1899 or visit trialnet.org
- Screening test kits are also available by mail. We will send you a test kit to take to a local lab to draw your blood sample. Screening is offered at no cost to you. You will learn the results in about 6 weeks.
It is important to know:
- Children under 18 years of age who do not have autoantibodies can be retested every year to see if their risk has changed.
- Finding autoantibodies in your blood tells us that you may be more likely to develop diabetes. Further testing by TrialNet will provide more information about your risk.
- Knowing your risk for diabetes gives you important information about your long-term health. It also lets you know if you are eligible to take part in a prevention study
If you are at risk for type 1 diabetes, there are research studies testing ways to prevent it. TrialNet is currently offering three prevention studies for relatives of people with type 1 diabetes. Depending on your risk level, you may be eligible to be in one of these studies:
Oral Insulin Prevention Trial
TrialNet is testing whether oral insulin (capsule taken by mouth) can help delay the onset of type 1 diabetes. An earlier study suggested that oral insulin might help delay the disease up to 10 years in persons with higher levels of insulin autoantibodies.
CTLA4-lg (Abatacept) Prevention Trial
Abatacept is a medication that has shown promise in preserving insulin production in people newly diagnosed with type 1 diabetes. The current study is testing whether abatacept can help delay or prevent the onset of type 1 diabetes.
AntiCD3 (Teplizumab) Prevention Trial
Teplizumab is a medication that has previously shown promise in preserving insulin production in people newly diagnosed with type 1 diabetes. This study is testing whether teplizumab can help delay or prevent the onset of the disease.
If you are not eligible to join a current prevention study, you can still be a part of TrialNet research. Even if you are not eligible to join a prevention study when you are first screened, you can continue to be closely monitored for the earliest signs of type 1
For more information or if you would like to get screened please contact:
Toll Free Number: 1.866.699.1899
Farah Sultan at 416.813.7654 ext 202634
For more information visit the Type 1 Diabetes TrialNet site at DiabetesTrialNet.org.